Discovery of GluA3 Preferring AMPA Receptor Positive Allosteric Modulator BRD3290
ACS Chemical Neuroscience · 29.10.2026
DOI: 10.1021/acschemneuro.6c00573 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, online erschienen am 29.10.2026. Verfasst von Christopher R Greaves und 18 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Stanley Family Foundation, Stanley Center for Psychiatric Research, Broad Institute.
Abstract (Originalsprache)
Schizophrenia is a debilitating neuropsychiatric disease that lacks effective treatments for many symptom domains including negative, cognitive and sleep disturbances. Lack of clear disease etiology has hampered the development of new, effective treatments for the unmet needs of people with schizophrenia. Large scale human genetics have identified rare loss of function mutations that substantially increase risk of developing schizophrenia, including in GRIA3, the gene that encodes the GluA3 receptor subunit of the AMPA receptor (AMPAR). Several drug discovery programs have been aimed at developing AMPAR positive allosteric modulators (PAMs) as a novel treatment for schizophrenia. Despite intense drug discovery efforts, there are no FDA approved AMPAR PAMs. We therefore hypothesized that selectively targeting GluA3, the AMPAR subunit implicated by human genetics, could yield a safer and more effective AMPAR PAM for the potential treatment of schizophrenia. Using a combination of medicinal chemistry, in vitro, and in vivo studies, we discovered BRD3290, a GluA3-preferring AMPAR PAM with reasonable potency in heterologous cells, as well as favorable tolerability and brain exposure. Peripheral administration of BRD3290 engaged an established AMPAR PAM target engagement biomarker but did not improve performance of wildtype mice in the novel object recognition task (NOR), in contrast to the nonselective AMPAR PAM PF-4778574, which improved mouse NOR. These findings suggest that the GluA3 selectivity profile of BRD3290 was insufficient to enhance cognitive function in this mouse NOR paradigm. This work highlights the challenges of AMPAR subtype-selective modulation and provides molecular insights into the ability to develop subtype-selective AMPAR PAMs.
Förderung
- Stanley Family Foundation
- Stanley Center for Psychiatric Research, Broad Institute
Zitieren
APA
Greaves, C. R., Martenis, W. E., Nelson, S. D., Madison, J., Skepner, A., Baez-Nieto, D., Stalnaker, K. J., Lebois, E. P., Campbell, A. J., Pelham, K., Magdei, M., Guletsky, A., Arce, K. P. D., Zhang, Y., Wagner, F. F., Pan, J. Q., Weïwer, M., Sheng, M., & Moran, S. P. (2026). Discovery of GluA3 Preferring AMPA Receptor Positive Allosteric Modulator BRD3290. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.6c00573
Vancouver
Greaves CR, Martenis WE, Nelson SD, Madison J, Skepner A, Baez-Nieto D, et al. Discovery of GluA3 Preferring AMPA Receptor Positive Allosteric Modulator BRD3290. ACS Chemical Neuroscience. 2026. doi:10.1021/acschemneuro.6c00573
BibTeX
@article{Greaves2026,
author = {Greaves, Christopher R and Martenis, William E and Nelson, Shawn D and Madison, Jon and Skepner, Adam and Baez-Nieto, David and Stalnaker, Katherine J and Lebois, Evan P and Campbell, Arthur J and Pelham, Katie and Magdei, Mihaela and Guletsky, Alex and Arce, Karen Perez de and Zhang, Yan-Ling and Wagner, Florence F and Pan, Jen Q and Weïwer, Michel and Sheng, Morgan and Moran, Sean P},
title = {Discovery of GluA3 Preferring AMPA Receptor Positive Allosteric Modulator BRD3290},
journal = {ACS Chemical Neuroscience},
year = {2026},
doi = {10.1021/acschemneuro.6c00573}
}
EUVIMED